

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**RESIGNATION OF DIRECTOR; AND
APPOINTMENT OF EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER
AND AUTHORISED REPRESENTATIVE**

This announcement is made by MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company announces the following changes to the Board with effect from 22 October 2026:

Resignation of Director

Dr. Zhaohua Chang (“**Dr. Chang**”) has resigned as a Director and related positions due to other personal commitments.

Dr. Chang has confirmed to the Company that he has no disagreement with the Board and that there is no matter relating to the resignation of Dr. Chang that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

Dr. Chang will continue to serve the Group as the Chief Scientific Officer of the Company and will focus on the promotion of cutting-edge technological innovation and other related matters.

The Company would like to express its sincere gratitude to Dr. Chang for his dedicated efforts and valuable contributions to the Group.

Appointment of Executive Director, Chief Executive Officer and Authorised Representative

Mr. Jonathan W. Chen (“**Mr. Chen**”) was appointed as the executive Director, the Chief Executive Officer and an authorised representative of the Company under Rule 3.05 of the Listing Rules on 22 October 2026.

Mr. Chen, born in 1975, joined the Group in July 2012, and has held senior leadership roles within the Group for more than 14 years. He holds directorships in certain subsidiaries of the Group. He has also served as the Executive Vice President of International Operations and Investor Relations, Chief International Business Officer, Rotating Co-Chief Executive Officer and Rotating Chief Executive Officer of the Company. Over the years, Mr. Chen’s primary responsibilities included expanding the Company’s international business in markets of the U.S., Europe, Asia Pacific and South America. He has built and maintained long-standing relationships of trust with business partners, distributors, hospitals, physicians and investors across the U.S., Europe, Asia Pacific and Latin America, and has led complex cross-border transactions, partnerships and regulatory approvals on behalf of the Group. Mr. Chen was the director and chairman of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (listed on Shanghai Stock Exchange (stock code: 688016), a subsidiary of the Company) from November 2023 to December 2025.

Mr. Chen was a non-executive director of Lombard Medical, Inc. (incorporated in the Cayman Islands and formerly listed on NASDAQ (stock code: EVAR)), from December 2016 to April 2018. Such company developed, manufactured and sold endovascular aortic stent products together with its subsidiaries. In April 2018, the company was liquidated and restructured in accordance with the laws of the Cayman Islands due to continuous operating losses and its inability to repay due debts. According to the reorganization plan, Endovascular Technology Corporation, a newly established company, acquired 100% of shares of Lombard Medical Limited and Lombard Medical Technologies GmbH at an aggregate consideration of US\$17 million, which preserved the core operating business and assets of the company. The relevant reorganization was completed in June 2018. At the same time, Lombard Medical, Inc. was placed into liquidation by a liquidator appointed by the Grand Court of the Cayman Islands. It was later dissolved.

Mr. Chen has over 29 years of experience in the medical device and life sciences industries. Prior to joining the Company, Mr. Chen successively served as the vice president and senior vice president of business development and financial strategy at Angiotech Pharmaceuticals, Inc. He led the management team to build a diversified medical products business through several transformational acquisitions and licensing transactions. Prior to joining Angiotech, Mr. Chen was a life sciences investment banker at Credit Suisse, Alex. Brown & Sons and Deutsche Bank where he advised his clients on equity and debt financing as well as mergers & acquisitions transactions.

Mr. Chen holds a Bachelor of Arts degree in Economics and a Bachelor of Sciences degree with honors in Biological Sciences from Stanford University.

As at the date of this announcement, Mr. Chen is interested in (i) 2,677,360 underlying shares of the Company by virtue of the share options granted to him under the share scheme(s) of the Company and (ii) 800,000 shares of the Company through a company wholly-owned by him. In addition, as at the date of this announcement, Mr. Chen is interested in 56,036 shares of Shanghai MicroPort MedBot (Group) Co., Ltd., an associated corporation of the Company (within the meaning of Part XV of the Securities and Futures Ordinance). Save as disclosed above, Mr. Chen does not have any other interests in the securities of the Company or its associated corporations which are required to be disclosed under Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Chen has not held any directorship in other listed public companies in Hong Kong or overseas in the last three years, and Mr. Chen does not hold any other positions with the Company or any of its subsidiaries. Mr. Chen is not related to any Directors, senior management, other substantial or controlling shareholders (as defined in the Listing Rules) of the Company.

Mr. Chen will enter into a service agreement with the Company as an executive Director, subject to rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Mr. Chen's appointment as an executive Director will be subject to an initial probationary period of one year commencing on the effective date of his appointment. Mr. Chen will not receive any emolument for serving as the executive Director. Mr. Chen's existing remuneration package will remain unchanged, comprising a basic salary and discretionary bonus, which is determined by the Board at the recommendation of the remuneration committee of the Company with reference to his duties and responsibilities within the Group, experience and qualifications and prevailing market conditions.

As at the date of this announcement, save as disclosed in this announcement, there is no information which is discloseable nor is Mr. Chen involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning the appointment of Mr. Chen that need to be brought to the attention of the Shareholders.

The Board hereby expresses its warmest welcome to Mr. Chen for joining the Board.

Enhancement of Corporate Governance

The Board is committed to enhancing the Company's corporate governance and strengthening its management structure. To this end, the following measures will be adopted:

(1) Enhancement of corporate governance and authorization arrangements

The Company will review its governance structure, the division of responsibilities between the Board and management of the Company, and its decision-making procedures, including the allocation of authority, authorisation arrangements and reporting mechanisms.

As part of the review, the Company will further enhance its governance policies and guidelines setting out clearly matters requiring approval of the Board, including the cancellation of any corporate governance structure and/or management organisation established or implemented without the Board's formal approval, must not be proceeded with. Any matter that should be approved by the Board but is proceeded without approval will be treated as unauthorised and should be reported promptly to the Board. Where there is any doubt as to whether a matter requires the Board approval or about the scope of delegated authority, the matter should be submitted to the Board for clarification before any action is taken.

(2) Strengthening management structure

With effect from Mr. Chen's appointment as the executive Director and the Chief Executive Officer, the Company will implement a CEO-led management structure under which Mr. Chen will be accountable to, and report directly to, the Board and will assume overall responsibility for the day-to-day management and operations of the Company. The Company will also establish a President's Office to assist Mr. Chen in discharging his management responsibilities and coordinating the work of the relevant functions.

By Order of the Board
MicroPort Scientific Corporation
Mr. Jonathan W. Chen
Executive Director

Shanghai, the People's Republic of China, 23 October 2026

As at the date of this announcement, the executive Director is Mr. Jonathan W. Chen; the non-executive Directors are Dr. Feng Gu, Ms. Jing Huang and Ms. Weiqin Sun; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu, Mr. Chunyang Shao and Dr. Yingyao Chen.

** For identification purposes only*